Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.33 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6832129 | 0.83 | GABRA1 (0.34) | GABRA1GABRB2 | |
| SCHEMBL3339715 | 0.69 | — | — | |
| SCHEMBL668146 | 0.66 | — | — | |
| SCHEMBL319464 | 0.66 | — | — | |
| SCHEMBL12242403 | 0.65 | NPC1 (0.32) | NPC1LMNAMAPK1CASP3RAB9A | |
| SCHEMBL24849937 | 0.64 | NPC1 (0.46) | NPC1LMNAMAPK1CASP3RAB9A | |
| SCHEMBL21737116 | 0.64 | — | — | |
| SCHEMBL21042229 | 0.64 | — | — | |
| SCHEMBL21737072 | 0.64 | — | — | |
| SCHEMBL29474236 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113555-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-06 | — | — | US | disclosed |
| US-20070185093-A1 | Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070082892-A1 | Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082892-A1 | Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands | CCKBR, GRPR, CCKAR | NPC1 2518/4885LMNA 4169/4885MAPK1 2611/4885 |
| US-20070185093-A1 | Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands | CCKBR, GRPR, CCKAR | NPC1 2518/4885LMNA 4169/4885MAPK1 2611/4885 |
| US-20100113555-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | NPC1 38/4885LMNA 3455/4885MAPK1 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.